Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Unresolved reference
External reference
10.1200/jco.2017.73.7585
10.1200/jco.2017.73.7585 · External reference
10.1200/jco.2017.75.6155
10.1200/jco.2017.75.6155 · External reference
10.1056/nejmoa2114663
10.1056/nejmoa2114663 · External reference
10.1056/nejmoa1903765
10.1056/nejmoa1903765 · External reference
10.1056/nejmoa1911149
10.1056/nejmoa1911149 · External reference
10.1056/nejmoa1607303
10.1056/nejmoa1607303 · External reference
10.1056/nejmoa1810527
10.1056/nejmoa1810527 · External reference
10.1038/s43018-024-00893-z
10.1038/s43018-024-00893-z · External reference
10.1146/annurev-med-070909-182917
10.1146/annurev-med-070909-182917 · External reference
10.3390/ijms24054522
10.3390/ijms24054522 · External reference
10.1016/j.ctrv.2024.102861
10.1016/j.ctrv.2024.102861 · External reference
10.1007/s11427-021-2140-8
10.1007/s11427-021-2140-8 · External reference
Randomized phase ii trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102
10.1200/jco.2017.76.9331 · 2018 · External reference
10.1056/nejmoa1109653
10.1056/nejmoa1109653 · External reference
10.1200/jco-24-02086
10.1200/jco-24-02086 · External reference
10.1056/nejmoa1813904
10.1056/nejmoa1813904 · External reference
10.1158/1557-3265.sabcs25-rf7-02
10.1158/1557-3265.sabcs25-rf7-02 · External reference
10.1056/nejmoa2214131
10.1056/nejmoa2214131 · External reference
10.1200/jco.22.00338
10.1200/jco.22.00338 · External reference
10.1056/nejmoa2410858
10.1056/nejmoa2410858 · External reference
10.1056/nejmoa1802905
10.1056/nejmoa1802905 · External reference
10.1056/nejmoa1706450
10.1056/nejmoa1706450 · External reference
10.1016/j.cell.2017.07.029
10.1016/j.cell.2017.07.029 · External reference
10.3390/cells11162508
10.3390/cells11162508 · External reference
10.4143/crt.2022.001
10.4143/crt.2022.001 · External reference
10.1007/s10549-023-07010-1
10.1007/s10549-023-07010-1 · External reference
10.1038/s41523-026-00968-3
10.1038/s41523-026-00968-3 · External reference
10.1186/s13058-020-01320-8
10.1186/s13058-020-01320-8 · External reference
10.1056/nejmoa2501796
10.1056/nejmoa2501796 · External reference
10.1016/s1470-2045(24)00673-9
10.1016/s1470-2045(24)00673-9 · External reference
10.1158/1078-0432.ccr-10-1694
10.1158/1078-0432.ccr-10-1694 · External reference
10.1016/s1470-2045(17)30376-5
10.1016/s1470-2045(17)30376-5 · External reference
10.1038/s41523-024-00648-0
10.1038/s41523-024-00648-0 · External reference
VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in hormone receptor–Positive/HER2−/PIK3CA wild-type advanced breast cancer
10.1200/jco-25-02643 · 2026 · External reference
10.1158/1078-0432.ccr-14-1306
10.1158/1078-0432.ccr-14-1306 · External reference
10.1038/s41416-022-02025-9
10.1038/s41416-022-02025-9 · External reference
10.1016/s1470-2045(24)00034-2
10.1016/s1470-2045(24)00034-2 · External reference
10.1002/cpdd.615
10.1002/cpdd.615 · External reference
10.15252/embj.201693929
10.15252/embj.201693929 · External reference
10.1126/scitranslmed.3005747
10.1126/scitranslmed.3005747 · External reference
10.3390/ijms26125844
10.3390/ijms26125844 · External reference
Unresolved reference
External reference
10.1200/jco.2026.44.17_suppl.lba1008
10.1200/jco.2026.44.17_suppl.lba1008 · External reference
10.1200/jco-24-01865
10.1200/jco-24-01865 · External reference
PACE: a randomized phase ii study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4/6 inhibitor and aromatase inhibitor for hormone receptor–positive/Human epidermal growth factor receptor–negative metastatic breast cancer
10.1200/jco.23.01940 · 2024 · External reference
10.1001/jamanetworkopen.2024.61067
10.1001/jamanetworkopen.2024.61067 · External reference
10.1158/1078-0432.ccr-25-0992
10.1158/1078-0432.ccr-25-0992 · External reference
